期刊文献+

中国2015—2018年3个流感季节流感疫苗疑似预防接种异常反应监测数据分析 被引量:34

Study on surveillance data of adverse events following immunization of seasonal influenza vaccine in China during 2015-2018 influenza season
原文传递
导出
摘要 目的分析中国2015—2018年流感季节流感疫苗(InfV)疑似预防接种异常反应(AEFI)的发生特征。方法通过全国AEFI信息管理系统,收集中国(不包括中国香港、澳门和台湾数据)2015年9月1日至2018年8月31日流感季节接种InfV后发生AEFI的个案数据进行分析(含同时接种其他疫苗数据)。疫苗批签发剂次数据来源于中国食品药品检定研究院公布的批签发数据。3个流感季节分别为2015年9月1日至2016年8月31日,2016年9月1日至2017年8月31日,2017年9月1日至2018年8月31日;使用的疫苗分别为3价流感疫苗(IIV3)-Split、IIV3-Split(儿童型)、IIV3-subunit。计算AEFI发生率(/10万剂),采用描述流行病学方法分析3个流感季节AEFI的发生特征。结果2015—2018年流感季节共报告InfVAEFI 8464例,其中接种IIV3-split者为5646例,发生率为10.645/10万剂;IIV3-split(儿童型)为2818例,发生率为9.355/10万剂。不良反应中,报告例数最多的为发热(腋温≥37.1℃),共6207例,其中3554例出现高热(腋温≥38.6℃),发生率为4.274/10万剂。非严重异常反应中,报告较多的为过敏性皮疹(442例,0.531/10万剂)、血管性水肿(70例,0.084/10万剂);严重异常反应发生率较低,其中报告较多的为热性惊厥(27例,0.032/10万剂)、过敏性紫癜(21例,0.025/10万剂)。结论中国InfV接种后严重AEFI报告发生率较低;所有不良反应中,发热报告例数最多。非严重异常反应过敏性皮疹和血管性水肿报告例数较多,严重异常反应报告发生率低。 Objective To analyze the occurrence features of adverse events following immunization(AEFI)of Seasonal Influenza Vaccines(InfV)used in China,2015-2018 influenza season.Methods InfV(including concurrent administered with other vaccines)AEFI data were collected through the Chinese national AEFI information system during 2015.9.1-2018.8.31(excluding Chinese Hong Kong,Macao and Taiwan data).The vaccine lot release data were collected from National Institutes for Food and Drug Control published database.Time periods of three influenza season were 2015.9.1-2016.8.31,2016.9.1-2017.8.31,2017.9.1-2018.8.31.The vaccines used and included in this analysis were trivalent inactivated influenza vaccine(IIV3)-Split,IIV3-Split(Children)and IIV-subnit.The incidence of AEFI were calculated(per 100000 release doses),and epidemiological characteristic were analyzed using descriptive methodology.Results A total of 8464 InfV AEFIs were collected in 2015-2018 influenza season from National AEFI Information System,in which 5646 were IIV3-split,with the rate of 10.64/100000 release doses,2818 were IIV3-split(Children),with the rate of 9.355/100000 release doses.The most common symptom was fever(axillary temperature≥37.1℃)within vaccine reactions,with a number of 6207 cases.In which,there were 3554 cases with fever(axillary temperature≥38.6℃)and the estimated reporting rate was 4.274/100000 release doses.In all rare vaccine reactions,the most common diagnosis was anaphylactic rash(442,0.531/100000 release doses)and angioedema(70,0.084/100000 release doses).Even the rates of serious rare vaccine reactions were low,febrile Convulsion(27,0.032/100000 release doses)and Henoch-Sch?nlein Purpura(HSP)(21,0.025/100000 release doses)were relatively common in serious rare vaccine reactions during the study period.Conclusion The estimated rate of rare vaccine reactions related toInfV was relatively low.In all vaccine reactions,fever was the most common symptoms.The most common diagnosis of non-serious rare vaccine reaction were anaphylactic rash and angioedema.The incidence of serious rare vaccine reactions was low.
作者 武文娣 李克莉 许涤沙 叶家楷 肖奇友 王华庆 Wu Wendi;Li Keli;Xu Disha;Ye Jiakai;Xiao Qiyou;Wang Huaqing(Department of National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing 100050,China)
出处 《中华预防医学杂志》 CAS CSCD 北大核心 2019年第10期987-992,共6页 Chinese Journal of Preventive Medicine
关键词 流感疫苗 预防接种 不良反应 Influenza vaccines Vaccination Adverse events following immunization
  • 相关文献

参考文献7

二级参考文献86

  • 1王业军,张秋业.过敏性紫癜研究进展[J].齐鲁医学杂志,2005,20(5):457-458. 被引量:18
  • 2胡锦流,王仪,范刚,朱凤才,唐成余.流行性感冒裂解疫苗临床安全性及免疫原性研究[J].现代预防医学,2006,33(5):828-829. 被引量:23
  • 3刘民,刘改芬,赵伟,王岩,王莉,师伟.医务人员接种流感疫苗的效果及效益研究[J].中国全科医学,2006,9(9):708-711. 被引量:33
  • 4卫生部.2009年秋冬季甲型H1N1流感疫苗预防接种指导意见[s].2009-09-10.
  • 5Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial[J].The Lancet, 2009, 375 (9708) : 56-66.
  • 6Zhu FC, Wang H, Fang HH, et al. A Novel Influenza A(H1N1) Vaccine in Various Age Groups[J]. N Engl J Med, 2009, 361 (25): 2414-2423.
  • 7Clark TW, Pareek M, Hoschler K, et al. Trial of Influenza A ( H1N1 ) 2009 Monovalent MF59-Adjuvanted Vaccine--Preliminary Report [ J ]. N Engl J Med, 2009, 361 (25) : 2424-2435.
  • 8卫生部.2009年秋冬季甲型H1N1流行性感冒疫苗预防接种指导意见[S].2009-09-19.
  • 9US. Summary of 2009 Monovalent H1N1 Influenza Vaccine Data-Vaccine Adverse Event Reporting System Data through May 29, 2010[EB]. (Accessed on June 30, 2010, at http://vaers.hhs.gov/resources/2010 H1N1Summary_June03.pdf ).
  • 10谢广钟,刁连东,王树巧,等.预防接种的反应和处理[M].第3版,上海:上海科学技术出版社,2009:113-115.

共引文献112

同被引文献334

引证文献34

二级引证文献436

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部